Education
About Us
Working with TipRanks
Follow Us
Madrigal (MDGL)
:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$200.08 - $377.46
Previous CloseN/A
Volume47.78K
Average Volume (3M)337.38K
Market Cap
$7.00B
Enterprise Value$5.96B
Total Cash (Recent Filing)$183.65M
Total Debt (Recent Filing)$119.77M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 06, 2025EPS Estimate
-3.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.11
Shares Outstanding22,080,246
10 Day Avg. Volume385,282
30 Day Avg. Volume337,385
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit34.24
Enterprise Value/Ebitda-15.83
Forecast
1Y Price Target
$424.21Price Target Upside34.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Madrigal Pharmaceuticals News
PremiumCompany Announcements
Madrigal Pharmaceuticals Reports Strong Q1 2025 Results
PremiumCompany Announcements
Madrigal’s Earnings Call: Rezdiffra’s Success and Future Plans---
Bulls Say, Bears Say
Bulls Say
Commercial LaunchRezdiffra's launch is gaining momentum, with strong patient demand and favorable physician prescribing trends.
Market PositionRezdiffra is expected to leverage a significant first-mover advantage with EASL guidelines recommending it as a first-line treatment for non-cirrhotic MASH.
Sales PerformanceProduct sales of Rezdiffra beat both our expectations and Street consensus for the quarter, coming in at $137.3M, representing 33% sequential growth.
Bears Say
Market ChallengesSeveral looming headwinds cloud the growth picture.
Prescription TrendsUncertainties remain over reauthorizations, impact of GLP-1s on uptake/pricing, decline in the initial bolus of diagnosed patients, lingering skepticism among prescribers, and launch of the FGF21s.
Product RoleWhile the liver-stiffness data is encouraging, caution is advised on Rezdiffra’s role in cirrhotic patients.
---
Ownership Overview
19.56% Insiders
25.96% Mutual Funds
0.25% Other Institutional Investors
40.11% Public Companies and
Individual Investors
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $200.08 and its highest was $377.46 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $7.00B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Aug 06, 2025 which is in 94 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on May 01, 2025. The company reported -$3.32 earnings per share for the quarter, beating the consensus estimate of -$3.749 by $0.429.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -3.49.
How many shares outstanding does Madrigal have?
Madrigal has 22,080,246 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$3.32 in its last earnings report, beating expectations of -$3.749. Following the earnings report the stock price went down -1.86%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
---
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$424.21 (34.46% Upside)
$424.21 (34.46% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.61%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
---
MDGL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted the successful launch and significant growth of Rezdiffra, with strong financial performance and upcoming regulatory milestones in Europe. However, there are challenges with increased operational expenses and uncertainties in the European market strategy.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$424.21
▲(34.46% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
---